HUTCHMED (China) Ltd
sovleplenib
warm antibody autoimmune hemolytic anemia
Resolved
26days ago
Phase 3 readout · Jun 11, 2026
What's at stake
Phase 3 trial results for sovleplenib in warm antibody autoimmune hemolytic anemia are due Jun 11, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“results from the Phase III part of the ESLIM-02 study of sovleplenib in patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China were presented on Thursday, June 11, 2026 during the European Hematology Association (“EHA”) ”